Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Patient and Kidney Allograft Survival in Recipients With End-Stage Renal Disease From Amyloidosis.

Sawinski D, Lim MA, Cohen JB, Locke JE, Weiss B, Hogan JJ, Dember LM.

Transplantation. 2018 Feb;102(2):300-309. doi: 10.1097/TP.0000000000001930.

PMID:
28885498
2.

High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.

Batalini F, Econimo L, Quillen K, Sloan JM, Sarosiek S, Brauneis D, Havasi A, Stern L, Dember LM, Sanchorawala V.

Biol Blood Marrow Transplant. 2018 Jan;24(1):127-132. doi: 10.1016/j.bbmt.2017.08.031. Epub 2017 Sep 1.

3.

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.

Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M.

Blood. 2011 Oct 20;118(16):4346-52. doi: 10.1182/blood-2011-01-330738. Epub 2011 Aug 9.

4.

Kidney dysfunction during lenalidomide treatment for AL amyloidosis.

Specter R, Sanchorawala V, Seldin DC, Shelton A, Fennessey S, Finn KT, Zeldis JB, Dember LM.

Nephrol Dial Transplant. 2011 Mar;26(3):881-6. doi: 10.1093/ndt/gfq482. Epub 2010 Aug 5.

5.

Modern treatment of amyloidosis: unresolved questions.

Dember LM.

J Am Soc Nephrol. 2009 Mar;20(3):469-72. doi: 10.1681/ASN.2008070793. Epub 2008 Dec 10. Review.

6.

Eprodisate for the treatment of renal disease in AA amyloidosis.

Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Pu├ęchal X, Lachmann HJ, Obici L, Balshaw R, Garceau D, Hauck W, Skinner M; Eprodisate for AA Amyloidosis Trial Group.

N Engl J Med. 2007 Jun 7;356(23):2349-60.

7.

Amyloidosis-associated kidney disease.

Dember LM.

J Am Soc Nephrol. 2006 Dec;17(12):3458-71. Epub 2006 Nov 8. Review.

8.

Dialysis-related amyloidosis: late finding or hidden epidemic?

Dember LM, Jaber BL.

Semin Dial. 2006 Mar-Apr;19(2):105-9. Review.

PMID:
16551286
9.

Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis.

Akar H, Seldin DC, Magnani B, O'Hara C, Berk JL, Schoonmaker C, Cabral H, Dember LM, Sanchorawala V, Connors LH, Falk RH, Skinner M.

Amyloid. 2005 Dec;12(4):210-5.

PMID:
16399645
10.

Emerging treatment approaches for the systemic amyloidoses.

Dember LM.

Kidney Int. 2005 Sep;68(3):1377-90. No abstract available.

11.

Case records of the Massachusetts General Hospital. Case 15-2005. An 80-year-old man with shortness of breath, edema, and proteinuria.

Dember LM, Shepard JA, Nesta F, Stone JR.

N Engl J Med. 2005 May 19;352(20):2111-9. No abstract available.

PMID:
15901865
12.

Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.

Seldin DC, Anderson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K, Finn KT, Berk JL, Dember LM, Falk RH, Skinner M.

Blood. 2004 Sep 15;104(6):1888-93. Epub 2004 May 20.

13.

High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.

Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG.

Ann Intern Med. 2004 Jan 20;140(2):85-93.

PMID:
14734330
14.

Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis.

Berk JL, Keane J, Seldin DC, Sanchorawala V, Koyama J, Dember LM, Falk RH.

Chest. 2003 Sep;124(3):969-77.

PMID:
12970025
15.

Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis.

Fadia A, Casserly LF, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM.

Kidney Int. 2003 May;63(5):1868-73.

16.

Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis.

Seldin DC, Choufani EB, Dember LM, Wiesman JF, Berk JL, Falk RH, O'Hara C, Fennessey S, Finn KT, Wright DG, Skinner M, Sanchorawala V.

Clin Lymphoma. 2003 Mar;3(4):241-6.

PMID:
12672274
17.

High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease.

Casserly LF, Fadia A, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM.

Kidney Int. 2003 Mar;63(3):1051-7.

18.

Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis.

Sanchorawala V, Wright DG, Seldin DC, Falk RH, Berk JL, Dember LM, Finn KT, Skinner M.

Br J Haematol. 2002 Jun;117(4):886-9.

PMID:
12060126

Supplemental Content

Loading ...
Support Center